Avalo Therapeutics
AVTX
20 hedge funds and large institutions have $68.3M invested in Avalo Therapeutics in 2018 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 4 closing their positions.
1,790% more capital inflows, than outflows
Capital inflows: $13.2M | Capital outflows: $701K
0.43% more ownership
Funds ownership: 52.03% → 52.46% (+0.43%)
0% more funds holding
Funds holding: 20 → 20 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$8.46M |
| 2 |
Armistice Capital
New York
|
+$2.43M |
| 3 |
Prosight Management
Dallas,
Texas
|
+$1.19M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$802K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$123K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$189K |
| 2 |
O'Shaughnessy Asset Management
Stamford,
Connecticut
|
-$100K |
| 3 |
Dumont & Blake Investment Advisors
Princeton,
New Jersey
|
-$93K |
| 4 |
Goldman Sachs
New York
|
-$81K |
| 5 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$66.9K |
AVTX Hedge Fund Activity: Q4 2018 in Review
20 of the 4,506 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q4 2018, worth a combined $68.3M — down 19% from $84.7M a quarter earlier.
Fund positioning in AVTX was balanced in Q4 2018: 4 funds opened new positions, 4 closed out, 6 added to existing stakes and 7 trimmed.
The largest buyer was Opaleye Management, opening a new position worth an estimated $8.46M. The largest seller was Millennium Management, cutting an estimated $189K.
- 20 institutional investors held Avalo Therapeutics (AVTX) as of Q4 2018, unchanged from Q3 2018.
- Funds reported $68.3M of Avalo Therapeutics stock for Q4 2018, down 19% quarter-over-quarter.
- 4 funds opened new Avalo Therapeutics positions in Q4 2018 and 4 closed out, a net change of 0 holders.
- The largest Avalo Therapeutics buyer in Q4 2018 was Opaleye Management, an estimated $8.46M added.
- The largest Avalo Therapeutics seller in Q4 2018 was Millennium Management, an estimated $189K sold.
Based on aggregated 13F filings for Q4 2018.